Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years

Data de publicação:

Autores da FMUP

  • Fernando José Magro Dias

    Autor

Participantes de fora da FMUP

  • Imbrizi, M
  • Coy, CSR

Unidades de investigação

Abstract

Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule for the treatment of IBD, we still do not have drugs that promote disease remission in a generalized way. We carried out a narrative review on therapeutic advances in the treatment of IBD, the mechanisms of action, and the challenges facing the therapeutic goals in the treatment of IBD. Salicylates are still used in the treatment of Ulcerative Colitis. Corticosteroids have an indication restricted to the period of therapeutic induction due to frequent adverse events, while technologies with less systemic action have been developed. Most immunomodulators showed a late onset of action, requiring a differentiated initial strategy to control the disease. New therapeutic perspectives emerged with biological therapy, initially with anti-TNF, followed by anti-integrins and anti-interleukins. Despite the different mechanisms of action, there are similarities between the general rates of effectiveness. These similar results were also evidenced in JAK inhibitors and S1p modulators, the last therapeutic classes approved for the treatment of IBD.

Dados da publicação

ISSN/ISSNe:
1424-8247, 1424-8247

Pharmaceuticals  Multidisciplinary Digital Publishing Institute (MDPI)

Tipo:
Review
Páginas:
-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 1

Citações Recebidas na Scopus: 13

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Crohn's disease; ulcerative colitis; 5-ASA; corticosteroid; immunomodulator; biological therapy; JAK; s1P

Financiamento

Proyectos asociados

Gut microbiome and IBD therapy: an interplay?

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (GutIBD) . 2021

Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (IronIBD) . 2021

Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (4WARD) . 2021

Isolated Ulceration of Crohn’s Anastomosis

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2022

Burden of Inflammatory Bowel Disease in Portugal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico (Inflammatory Bowel) . 2023

Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação